NCT04364789View on ClinicalTrials.gov

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

June 18, 2021

Study Completion Date

March 17, 2022

Conditions
Healthy
Interventions
DRUG

TT-00920

Tablets

DRUG

Placebos

Tablets

Trial Locations (1)

91206

Early Phase Clinical Unit Glendale Adventist Medical Center, Los Angeles

All Listed Sponsors
lead

TransThera Sciences (Nanjing), Inc.

INDUSTRY

NCT04364789 - Phase I, First-In-Human Study of TT-00920 in Healthy Subjects | Biotech Hunter | Biotech Hunter